The Insulin-Only Bionic Pancreas Bridging Study

Status Completed

Clinical Trial Summary

The iLet is a closed-loop delivery system that can be used in insulin-only, bihormonal, or glucagon-only configurations. Previous studies have utilized a phone-based bionic pancreas. The iLet consists of a touchscreen-enabled, menu-driven user interface and an onboard microprocessor that provides a comprehensive and standalone platform, which allows the iLet to operate independently of smartphones or other devices and without the need for internet support during routine operation.

This is a multicenter study of adult participants with type 1 diabetes, who will manage their diabetes with the iLet bionic pancreas compared to usual care.

Clinical Trial Description

This study will serve as a transitional study, bridging to larger and longer outpatient pivotal studies using the insulin-only configuration of the bionic pancreas.

The Adult RCT Period will consist of a multi-center, three-period, random-order, cross-over, feasibility study in 36 adult participants ≥ 18 years old with T1D. Insulin therapy for each participant will be administered (i) using the iLet in the insulin-only configuration and the insulin analog that they use for their usual care (either Humalog or Novolog) for 7 days, (ii) in another period using the iLet in the insulin-only configuration with faster insulin aspart (Fiasp) for 7 days (iii) in a third period using the participant's own usual care (UC) for 7 days. All three experimental periods will be followed by round-the-clock, remote, telemetric monitoring for hyperglycemia (> 300 mg/dl for ≥ 90 minutes) and hypoglycemia (< 50 mg/dl for ≥ 15 minutes). Half the subjects enrolled were expected to manage their diabetes with MDI and the other half with insulin pumps in their UC. An implantable Eversense CGM will also be placed in half the study participants for a CGM comparison. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03565666
Study type	Interventional
Source	Massachusetts General Hospital
Contact
Status	Completed
Phase	Phase 2/Phase 3
Start date	July 9, 2018
Completion date	November 19, 2018

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03623113` - The Dietary Education Trial in Carbohydrate Counting (DIET-CARB Study in Type 1 Diabetes	N/A
Withdrawn	`NCT03396484` - Methyldopa for Reduction of DQ8 Antigen Presentation in At-Risk Subjects for Type 1 Diabetes	Phase 2
Completed	`NCT03117998` - Multiple Dose Study to Evaluate the Efficacy, Safety and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus	Phase 2
Recruiting	`NCT03369821` - EXtremely Early-onset Type 1 Diabetes EXtremely Early-onset Type 1 Diabetes (A Musketeers' Memorandum Study)
Completed	`NCT03202732` - DiabetesFlex - Patient Involvement and Patient-reported Outcome Measures in Type 1 Diabetes	N/A
Completed	`NCT03704818` - Dapagliflozin Effects on Hypoglycemia	Phase 1
Recruiting	`NCT03864991` - Lifestyle Changes and Glycemic Control in T1D	N/A
Completed	`NCT03725657` - Correlation Between Exercise and Insulin Dose in a Camp for Pediatric Type 1 Patients
Completed	`NCT02985866` - The International Diabetes Closed Loop (iDCL) Trial: Protocol 1	N/A
Completed	`NCT03003806` - Evaluation of the Dreamed Advisor Pro for Automated Insulin Pump Setting Adjustments in Children and Adolescents With Type 1 Diabetes- The Advice4U Pro Study	N/A
Withdrawn	`NCT04147637` - FreeStyle Libre Plus Bluetooth Transmitter Adjunct: Can This Improve Glucose Accuracy and Reduce Burden of Hypoglycaemia	N/A
Completed	`NCT03970889` - Real-time Reminders To Decrease Late or Missed Meal Boluses	N/A
Recruiting	`NCT04589325` - Ixekizumab Diabetes Intervention Trial (I-DIT)	Phase 2
Completed	`NCT03367390` - A Study of an Automated Insulin Delivery System in Participants With Type 1 Diabetes Mellitus (T1DM)	Phase 1
Completed	`NCT03738852` - Mechanisms for Restoration of Hypoglycemia Awareness	Early Phase 1
Completed	`NCT03406585` - Wharton´s Jelly Derived Mesenchymal Stromal Cell Treatment of Adult Patients Diagnosed With Type I Diabetes	Phase 1/Phase 2
Completed	`NCT03859856` - Ovarian Reserve in Diabetes Mellitus
Withdrawn	`NCT04102202` - BOL-DP-o-05 as an Add-On Treatment of Subjects With Newly Diagnosed Type 1 Diabetes Mellitus	Phase 1/Phase 2
Terminated	`NCT03353792` - Using an Artificial Pancreas System in Older Adult Type 1 Diabetes Mellitus Patients	N/A
Recruiting	`NCT03811470` - China Diabetes Registry by Metabolic Management Center